Study protocol: developing, disseminating, and implementing a core outcome set for selective fetal growth restriction in monochorionic twin pregnancies.
Consensus
Consensus Development Conferences as Topic
Delphi Technique
Diseases in Twins
/ diagnosis
Endpoint Determination
Female
Fetal Growth Retardation
/ diagnosis
Humans
Pregnancy
Pregnancy, Twin
Research Design
Stakeholder Participation
Systematic Reviews as Topic
Treatment Outcome
Twins, Monozygotic
Consensus development study
Core outcome set
Modified Delphi method
Modified Nominal Group Technique
Selective fetal growth restriction
Selective intrauterine growth restriction
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
09 Jan 2019
09 Jan 2019
Historique:
received:
19
07
2018
accepted:
18
12
2018
entrez:
11
1
2019
pubmed:
11
1
2019
medline:
8
5
2019
Statut:
epublish
Résumé
Selective fetal growth restriction in monochorionic twin pregnancies is associated with an increased risk of perinatal mortality and morbidity and represents a clinical dilemma. Interventions include expectant management with early preterm delivery if there are signs of fetal compromise, selective termination of the compromised twin, fetoscopic laser coagulation of the communicating placental vessels or termination of the whole pregnancy. Previous studies evaluating interventions have reported many different outcomes and outcome measures. Such variation makes comparing, contrasting, and combining results challenging, limiting ongoing research on this uncommon condition to inform clinical practice. We aim to produce, disseminate, and implement a core outcome set for selective fetal growth restriction research in monochorionic twin pregnancies. An international steering group, including professionals, researchers, and lay experts, has been established to oversee the development of this core outcome set. The methods have been guided by the Core Outcome Measures in Effectiveness Trials Initiative Handbook. Potential core outcomes will be developed by undertaking a systematic review of studies evaluating interventions for selective fetal growth restriction in monochorionic twin pregnancies. Potential core outcomes will be entered into a three-round Delphi survey and key stakeholders including clinical professionals, researchers, and lay experts will be invited to participate. Repeated reflection and rescoring of individual outcomes should encourage group and individual stakeholder convergence towards consensus outcomes which will be entered into a modified Nominal Group Technique to finalize the core outcome set. Once core outcomes have been agreed, we will establish standardized definitions and recommend high-quality measurement instruments for each outcome. The development, dissemination, and implementation of a core outcome set for selective fetal growth restriction should ensure that future research protocols select, collect, and report outcomes and outcome measures in a standardized manner. Data synthesis will be possible on a broad level and rigorous implementation should advance the quality of research studies and their effective use in order to guide clinical practice, improve patient care, maternal, short-term perinatal outcomes, and long-term neurodevelopmental outcomes. Core Outcome Measures in Effectiveness Trials (COMET) registration number: 998. International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42018092697 . 18th April 2018.
Sections du résumé
BACKGROUND
BACKGROUND
Selective fetal growth restriction in monochorionic twin pregnancies is associated with an increased risk of perinatal mortality and morbidity and represents a clinical dilemma. Interventions include expectant management with early preterm delivery if there are signs of fetal compromise, selective termination of the compromised twin, fetoscopic laser coagulation of the communicating placental vessels or termination of the whole pregnancy. Previous studies evaluating interventions have reported many different outcomes and outcome measures. Such variation makes comparing, contrasting, and combining results challenging, limiting ongoing research on this uncommon condition to inform clinical practice. We aim to produce, disseminate, and implement a core outcome set for selective fetal growth restriction research in monochorionic twin pregnancies.
METHODS
METHODS
An international steering group, including professionals, researchers, and lay experts, has been established to oversee the development of this core outcome set. The methods have been guided by the Core Outcome Measures in Effectiveness Trials Initiative Handbook. Potential core outcomes will be developed by undertaking a systematic review of studies evaluating interventions for selective fetal growth restriction in monochorionic twin pregnancies. Potential core outcomes will be entered into a three-round Delphi survey and key stakeholders including clinical professionals, researchers, and lay experts will be invited to participate. Repeated reflection and rescoring of individual outcomes should encourage group and individual stakeholder convergence towards consensus outcomes which will be entered into a modified Nominal Group Technique to finalize the core outcome set. Once core outcomes have been agreed, we will establish standardized definitions and recommend high-quality measurement instruments for each outcome.
DISCUSSION
CONCLUSIONS
The development, dissemination, and implementation of a core outcome set for selective fetal growth restriction should ensure that future research protocols select, collect, and report outcomes and outcome measures in a standardized manner. Data synthesis will be possible on a broad level and rigorous implementation should advance the quality of research studies and their effective use in order to guide clinical practice, improve patient care, maternal, short-term perinatal outcomes, and long-term neurodevelopmental outcomes.
TRIAL REGISTRATION
BACKGROUND
Core Outcome Measures in Effectiveness Trials (COMET) registration number: 998. International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42018092697 . 18th April 2018.
Identifiants
pubmed: 30626413
doi: 10.1186/s13063-018-3153-y
pii: 10.1186/s13063-018-3153-y
pmc: PMC6327411
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Références
Ultrasound Obstet Gynecol. 2007 Jul;30(1):28-34
pubmed: 17542039
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Fetal Diagn Ther. 2010;27(3):121-33
pubmed: 20413975
Implement Sci. 2010 Nov 22;5:91
pubmed: 21092164
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
Am J Obstet Gynecol. 1990 May;162(5):1230-6
pubmed: 2187353
Prenat Diagn. 2013 Feb;33(2):109-15
pubmed: 23280487
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
BJOG. 2014 Sep;121(10):1181-2
pubmed: 24889142
Trials. 2014 Jun 25;15:247
pubmed: 24962012
Fetal Diagn Ther. 2016;39(3):186-91
pubmed: 26344150
Am J Obstet Gynecol. 2016 Apr;214(4):452-464
pubmed: 26778385
BJOG. 2016 Sep;123(10):1599
pubmed: 27428666
Curr Opin Obstet Gynecol. 2016 Dec;28(6):485-491
pubmed: 27755130
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
Ultrasound Obstet Gynecol. 2017 Nov;50(5):559-568
pubmed: 27859836
Pregnancy Hypertens. 2016 Oct;6(4):274-278
pubmed: 27939467
BMJ Open. 2016 Dec 21;6(12):e013998
pubmed: 28003300
Contraception. 2017 May;95(5):437-441
pubmed: 28065833
BJOG. 2017 Sep;124(10):1481-1489
pubmed: 28421657
BJOG. 2017 Nov;124(12):1829-1839
pubmed: 28432737
Semin Fetal Neonatal Med. 2017 Dec;22(6):376-382
pubmed: 28532678
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Trials. 2017 Jul 14;18(1):325
pubmed: 28709445
Int J Gynaecol Obstet. 2017 Dec;139(3):262-267
pubmed: 28803445
BJOG. 2018 Jun;125(7):795-803
pubmed: 29030992
Ultrasound Obstet Gynecol. 2019 Jan;53(1):47-54
pubmed: 29363848
Ultrasound Obstet Gynecol. 2018 Nov;52(5):577-585
pubmed: 29607558
BMJ Paediatr Open. 2017 Jul 26;1(1):e000048
pubmed: 29637104
Best Pract Res Clin Obstet Gynaecol. 2018 May;49:79-88
pubmed: 29661565